Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;7(8):e2300062.
doi: 10.1002/adbi.202300062. Epub 2023 Jul 4.

Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling

Juan Zhang  1 , Hong-Xi Xu  2 , Yu-Lin Wu  1 , William Chi Shing Cho  3 , Yan-Fang Xian  1 , Zhi-Xiu Lin  1   4
Affiliations

Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling

Juan Zhang et al. Adv Biol (Weinh). 2023 Aug.

Abstract

Triple negative breast cancer (TNBC) is an aggressive cancer with very poor prognosis. Combination therapy has proven to be a promising strategy for enhancing TNBC treatment efficacy. Toosendanin (TSN), a plant-derived triterpenoid, has shown pleiotropic effects against a variety of tumors. Herein, it is evaluated whether TSN can enhance the efficacy of paclitaxel (PTX), a common chemotherapeutic agent, against TNBC. It is found that TSN and PTX synergistically suppress the proliferation of TNBC cell lines such as MDA-MB-231 and BT-549, and the combined treatment also inhibits the colony formation and induces cell apoptosis. Furthermore, this combination shows more marked migratory inhibition when compared to PTX alone. Mechanistic study shows that the ADORA2A pathway in TNBC is down-regulated by the combination treatment via mediating epithelial-to-mesenchymal transition (EMT) process. In addition, the combined treatment of TSN and PTX significantly attenuates the tumor growth when compared to PTX monotherapy in a mouse model bearing 4T1 tumor. The results suggest that combination of TSN and PTX is superior to PTX alone, suggesting that it may be a promising alternative adjuvant chemotherapy strategy for patients with TNBC, especially those with metastatic TNBC.

Keywords: apoptosis; cell migration; paclitaxel; toosendanin; triple negative breast cancer; tumor growth.

PubMed Disclaimer

References

    1. X. C. Hu, J. Zhang, B. H. Xu, L. Cai, J. Ragaz, Z. H. Wang, B. Y. Wang, Y. E. Teng, Z. S. Tong, Y. Y. Pan, Y. M. Yin, C. P. Wu, Z. F. Jiang, X. J. Wang, G. Y. Lou, D. G. Liu, J. F. Feng, J. F. Luo, K. Sun, Y. J. Gu, J. Wu, Z. M. Shao, Lancet Oncol. 2015, 16, 436.
    1. K. D. Yu, F. G. Ye, M. He, L. Fan, D. Ma, M. Mo, J. Wu, G. Y. Liu, G. H. Di, X. H. Zeng, P. Q. He, K. J. Wu, Y. F. Hou, J. Wang, C. Wang, Z. G. Zhuang, C. G. Song, X. Y. Lin, A. Toss, F. Ricci, Z. Z. Shen, Z. M. Shao, JAMA Oncol. 2020, 6, 1390.
    1. Y. Chen, R. Liu, C. Li, Y. Song, G. Liu, Q. Huang, L. Yu, D. Zhu, C. Lu, A. Lu, L. Li, Y. Liu, Am. J. Cancer Res. 2021, 11, 3445.
    1. L. J. Deng, M. Qi, N. Li, Y. H. Lei, D. M. Zhang, J. X. Chen, J. Leukocyte Biol. 2020, 108, 493.
    1. B. Y. Ho, C. H. Lin, M. K. Apaya, W. W. Chao, L. F. Shyur, J. Tradit. Complement. Med. 2012, 2, 301.

Publication types

MeSH terms

LinkOut - more resources